NervGen Pharma Corp.
NGENF
$4.41
$0.184.26%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.02M | -6.58M | -2.75M | -6.15M | -4.01M |
| Total Depreciation and Amortization | 10.10K | 10.10K | 9.70K | 11.30K | 10.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -636.80K | 3.35M | -376.30K | 2.99M | 144.50K |
| Change in Net Operating Assets | -217.00K | 573.50K | 247.70K | 531.00K | -363.00K |
| Cash from Operations | -3.86M | -2.65M | -2.87M | -2.61M | -4.22M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.30K | 18.20K | 17.60K | 18.00K | 18.50K |
| Cash from Investing | 18.30K | 18.20K | 17.60K | 18.00K | 18.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.20K | -25.20K | -25.20K | -25.20K | -25.20K |
| Issuance of Common Stock | 1.10M | 4.92M | 1.76M | 335.20K | 295.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -80.60K | -144.60K | -460.20K | 0.00 | 0.00 |
| Cash from Financing | 722.60K | 3.43M | 888.00K | 221.50K | 197.80K |
| Foreign Exchange rate Adjustments | -9.40K | 65.50K | 15.90K | -297.30K | -68.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.13M | 869.70K | -1.95M | -2.67M | -4.07M |